{"entity":{"id":"nct07617753","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","aka":[],"tldr":"A phase 1/2 trial of Cyclophosphamide in ovarian cancer, run by Beijing Biotech, now recruiting.","summary":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 is a phase 1/2 interventional study registered as NCT07617753 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-06-14. Interventions recorded: Dual-target CAR-NK cell product, Cyclophosphamide, supportive. Conditions listed: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07617753","url":"https://clinicaltrials.gov/study/NCT07617753"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07617753","phase":"1/2","setting":"A Phase 1/2, Open-Label, Biomarker-Assigned Study of Dual-Targeting CAR-NK Cells Directed Against Mesothelin (MSLN), Folate Receptor Alpha (FRα/FOLR1), and/or MUC16 (CA125) in Patients With Recurrent or Refractory High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","sponsor":"Beijing Biotech","enrolled":36,"outcomes":[]},"route":"/trials/nct07617753/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"}]}}